Update on the Safety of Andexxa by AstraZeneca: FDA Safety Communication

AUDIENCE: Patient, Health Care Professional, Pharmacy, Hematology ISSUE: Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Based on available data, the serious risks including the increase in thromboembolic events are such that the FDA considers the…

Custom Surgical Pack Recall: Alcon Removes Custom Pak Ophthalmic Procedure Packs

This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product The FDA is aware that Alcon has issued a letter to affected customers recommending certain…

Handelnine Global Limited d/b/a as Navafresh Issues Nationwide Recall of Rheumacare Capsules by Virgo UAP Pharma Pvt. Ltd. (Virgo), Due to Elevated Lead Levels

Summary Company Announcement Date: December 22, 2025 FDA Publish Date: December 22, 2025 Product Type: Drugs Reason for Announcement: Recall Reason Description Elevated levels of lead Company Name: Handelnine Global Limited d/b/a Navafresh Brand Name: Brand Name(s) Product Description: Product Description Rheumacare Capsules Company Announcement Handelnine Global Limited d/b/a Navafresh is voluntarily recalling Lot Numbers…